Neoadjuvant ultrahypofractionated radiotherapy with simultaneous integrated boost for glioblastoma: study protocol for a phase I multicenter clinical trial
Abstract
BACKGROUND: The Stupp protocol standardized adjuvant radiotherapy (RT) with temozolomide as the best treatment after glioblastoma (GBM) resection. Later phase III trials found that moderate hypofractionation and ultrahypofractionation were not inferior in elderly or frail patients. As most recurrences occurred near the tumor bed, RT margins could be reduced, favoring ultrahypofractionated RT (UHRT). Neoadjuvant UHRT might provide additional benefits by allowing better margin selection and lowering radionecrosis risk through the surgical removal of the irradiated tissue. METHODS: This is a phase I, single-arm, multicenter clinical trial having as primary endpoint the identification of maximum tolerated dose in operable GBM patients. A total dose of 30 Gy delivered in 5 fractions will be prescribed to planning target volume, with a simultaneous integrated boost dose escalation to gross tumor volume from 35 to 50 Gy, with 5 patients at each dose level. Dose to the next patient group will be escalated if toxicity target is met. The assumption is that not more than 30% of patients would present cumulative ≥G3 toxicity (CTCAE v5.0 scale) one month after the end of UHRT. A 30-patient sample size is predicted to result in a 2-sided 95% confidence interval with a width of 0.328 (0.136–0.464) when the sample proportion is 0.300. Four weeks after the end of UHRT, following a brain MRI, the lesion will be surgically removed. A peripheral blood sample will be taken before and after UHRT,…
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.